<?xml version='1.0' encoding='utf-8'?>
<document id="19026171"><sentence text="Determination of the inhibitory potential of 6 fluoroquinolones on CYP1A2 and CYP2C9 in human liver microsomes." /><sentence text="To determine the inhibitory potential of 2 new fluoroquinolones, caderofloxacin and antofloxacin, together with 4 marketed fluoroquinolones, moxifloxacin, gatifloxacin, levofloxacin, and ciprofloxacin, on the activity of cytochrome P450 isoforms 1A2 (CYP1A2) and 2C9 (CYP2C9)"><entity charOffset="65-79" id="DDI-PubMed.19026171.s2.e0" text="caderofloxacin" /><entity charOffset="84-96" id="DDI-PubMed.19026171.s2.e1" text="antofloxacin" /><entity charOffset="141-153" id="DDI-PubMed.19026171.s2.e2" text="moxifloxacin" /><entity charOffset="155-167" id="DDI-PubMed.19026171.s2.e3" text="gatifloxacin" /><entity charOffset="169-181" id="DDI-PubMed.19026171.s2.e4" text="levofloxacin" /><entity charOffset="187-200" id="DDI-PubMed.19026171.s2.e5" text="ciprofloxacin" /><pair ddi="false" e1="DDI-PubMed.19026171.s2.e0" e2="DDI-PubMed.19026171.s2.e0" /><pair ddi="false" e1="DDI-PubMed.19026171.s2.e0" e2="DDI-PubMed.19026171.s2.e1" /><pair ddi="false" e1="DDI-PubMed.19026171.s2.e0" e2="DDI-PubMed.19026171.s2.e2" /><pair ddi="false" e1="DDI-PubMed.19026171.s2.e0" e2="DDI-PubMed.19026171.s2.e3" /><pair ddi="false" e1="DDI-PubMed.19026171.s2.e0" e2="DDI-PubMed.19026171.s2.e4" /><pair ddi="false" e1="DDI-PubMed.19026171.s2.e0" e2="DDI-PubMed.19026171.s2.e5" /><pair ddi="false" e1="DDI-PubMed.19026171.s2.e1" e2="DDI-PubMed.19026171.s2.e1" /><pair ddi="false" e1="DDI-PubMed.19026171.s2.e1" e2="DDI-PubMed.19026171.s2.e2" /><pair ddi="false" e1="DDI-PubMed.19026171.s2.e1" e2="DDI-PubMed.19026171.s2.e3" /><pair ddi="false" e1="DDI-PubMed.19026171.s2.e1" e2="DDI-PubMed.19026171.s2.e4" /><pair ddi="false" e1="DDI-PubMed.19026171.s2.e1" e2="DDI-PubMed.19026171.s2.e5" /><pair ddi="false" e1="DDI-PubMed.19026171.s2.e2" e2="DDI-PubMed.19026171.s2.e2" /><pair ddi="false" e1="DDI-PubMed.19026171.s2.e2" e2="DDI-PubMed.19026171.s2.e3" /><pair ddi="false" e1="DDI-PubMed.19026171.s2.e2" e2="DDI-PubMed.19026171.s2.e4" /><pair ddi="false" e1="DDI-PubMed.19026171.s2.e2" e2="DDI-PubMed.19026171.s2.e5" /><pair ddi="false" e1="DDI-PubMed.19026171.s2.e3" e2="DDI-PubMed.19026171.s2.e3" /><pair ddi="false" e1="DDI-PubMed.19026171.s2.e3" e2="DDI-PubMed.19026171.s2.e4" /><pair ddi="false" e1="DDI-PubMed.19026171.s2.e3" e2="DDI-PubMed.19026171.s2.e5" /><pair ddi="false" e1="DDI-PubMed.19026171.s2.e4" e2="DDI-PubMed.19026171.s2.e4" /><pair ddi="false" e1="DDI-PubMed.19026171.s2.e4" e2="DDI-PubMed.19026171.s2.e5" /></sentence><sentence text="" /><sentence text="Probe substrates, phenacetin (CYP1A2), and tolbutamide (CYP2C9) were incubated with human liver microsomes and the metabolites were analyzed by liquid chromatography/mass spectrometry using electrospray ionization in positive or negative mode"><entity charOffset="18-28" id="DDI-PubMed.19026171.s4.e0" text="phenacetin" /><entity charOffset="30-36" id="DDI-PubMed.19026171.s4.e1" text="CYP1A2" /><entity charOffset="43-54" id="DDI-PubMed.19026171.s4.e2" text="tolbutamide" /><entity charOffset="56-62" id="DDI-PubMed.19026171.s4.e3" text="CYP2C9" /><pair ddi="false" e1="DDI-PubMed.19026171.s4.e0" e2="DDI-PubMed.19026171.s4.e0" /><pair ddi="false" e1="DDI-PubMed.19026171.s4.e0" e2="DDI-PubMed.19026171.s4.e1" /><pair ddi="false" e1="DDI-PubMed.19026171.s4.e0" e2="DDI-PubMed.19026171.s4.e2" /><pair ddi="false" e1="DDI-PubMed.19026171.s4.e0" e2="DDI-PubMed.19026171.s4.e3" /><pair ddi="false" e1="DDI-PubMed.19026171.s4.e1" e2="DDI-PubMed.19026171.s4.e1" /><pair ddi="false" e1="DDI-PubMed.19026171.s4.e1" e2="DDI-PubMed.19026171.s4.e2" /><pair ddi="false" e1="DDI-PubMed.19026171.s4.e1" e2="DDI-PubMed.19026171.s4.e3" /><pair ddi="false" e1="DDI-PubMed.19026171.s4.e2" e2="DDI-PubMed.19026171.s4.e2" /><pair ddi="false" e1="DDI-PubMed.19026171.s4.e2" e2="DDI-PubMed.19026171.s4.e3" /></sentence><sentence text=" Glipizide was used as the internal standard in both modes"><entity charOffset="1-10" id="DDI-PubMed.19026171.s5.e0" text="Glipizide" /></sentence><sentence text=" The inhibitory potential of fluoroquinolones on CYP1A2 and CYP2C9 was investigated"><entity charOffset="29-45" id="DDI-PubMed.19026171.s6.e0" text="fluoroquinolones" /></sentence><sentence text="" /><sentence text="The IC50 values (micromol/L) determined with the cocktail were in agreement with individual probe substrates (alpha-naphthoflavone: 0"><entity charOffset="110-130" id="DDI-PubMed.19026171.s8.e0" text="alpha-naphthoflavone" /></sentence><sentence text="27 vs 0" /><sentence text="26; sulfaphenazole: 0"><entity charOffset="4-18" id="DDI-PubMed.19026171.s10.e0" text="sulfaphenazole" /></sentence><sentence text="49 vs 0" /><sentence text="37)" /><sentence text=" Ciprofloxacin showed weak inhibition on both the activity of CYP1A2 (IC50 135 micromol/L) and CYP2C9 (IC50 180 micromol/L), whereas levofloxacin inhibited only CYP2C9 (IC50 210 micromol/L)"><entity charOffset="1-14" id="DDI-PubMed.19026171.s13.e0" text="Ciprofloxacin" /><entity charOffset="133-145" id="DDI-PubMed.19026171.s13.e1" text="levofloxacin" /><pair ddi="false" e1="DDI-PubMed.19026171.s13.e0" e2="DDI-PubMed.19026171.s13.e0" /><pair ddi="false" e1="DDI-PubMed.19026171.s13.e0" e2="DDI-PubMed.19026171.s13.e1" /></sentence><sentence text=" Caderofloxacin, antofloxacin, moxifloxacin, and gatifloxacin showed little or no inhibition on the activity of CYP1A2 or CYP2C9 when tested at comparable concentrations (0-200 mg/L)"><entity charOffset="1-15" id="DDI-PubMed.19026171.s14.e0" text="Caderofloxacin" /><entity charOffset="17-29" id="DDI-PubMed.19026171.s14.e1" text="antofloxacin" /><entity charOffset="31-43" id="DDI-PubMed.19026171.s14.e2" text="moxifloxacin" /><entity charOffset="49-61" id="DDI-PubMed.19026171.s14.e3" text="gatifloxacin" /><pair ddi="false" e1="DDI-PubMed.19026171.s14.e0" e2="DDI-PubMed.19026171.s14.e0" /><pair ddi="false" e1="DDI-PubMed.19026171.s14.e0" e2="DDI-PubMed.19026171.s14.e1" /><pair ddi="false" e1="DDI-PubMed.19026171.s14.e0" e2="DDI-PubMed.19026171.s14.e2" /><pair ddi="false" e1="DDI-PubMed.19026171.s14.e0" e2="DDI-PubMed.19026171.s14.e3" /><pair ddi="false" e1="DDI-PubMed.19026171.s14.e1" e2="DDI-PubMed.19026171.s14.e1" /><pair ddi="false" e1="DDI-PubMed.19026171.s14.e1" e2="DDI-PubMed.19026171.s14.e2" /><pair ddi="false" e1="DDI-PubMed.19026171.s14.e1" e2="DDI-PubMed.19026171.s14.e3" /><pair ddi="false" e1="DDI-PubMed.19026171.s14.e2" e2="DDI-PubMed.19026171.s14.e2" /><pair ddi="false" e1="DDI-PubMed.19026171.s14.e2" e2="DDI-PubMed.19026171.s14.e3" /></sentence><sentence text="" /><sentence text="Caderofloxacin, antofloxacin, moxifloxacin, and gatifloxacin are negligible inhibitors to CYP1A2 and CYP2C9"><entity charOffset="0-14" id="DDI-PubMed.19026171.s16.e0" text="Caderofloxacin" /><entity charOffset="16-28" id="DDI-PubMed.19026171.s16.e1" text="antofloxacin" /><entity charOffset="30-42" id="DDI-PubMed.19026171.s16.e2" text="moxifloxacin" /><entity charOffset="48-60" id="DDI-PubMed.19026171.s16.e3" text="gatifloxacin" /><pair ddi="false" e1="DDI-PubMed.19026171.s16.e0" e2="DDI-PubMed.19026171.s16.e0" /><pair ddi="false" e1="DDI-PubMed.19026171.s16.e0" e2="DDI-PubMed.19026171.s16.e1" /><pair ddi="false" e1="DDI-PubMed.19026171.s16.e0" e2="DDI-PubMed.19026171.s16.e2" /><pair ddi="false" e1="DDI-PubMed.19026171.s16.e0" e2="DDI-PubMed.19026171.s16.e3" /><pair ddi="false" e1="DDI-PubMed.19026171.s16.e1" e2="DDI-PubMed.19026171.s16.e1" /><pair ddi="false" e1="DDI-PubMed.19026171.s16.e1" e2="DDI-PubMed.19026171.s16.e2" /><pair ddi="false" e1="DDI-PubMed.19026171.s16.e1" e2="DDI-PubMed.19026171.s16.e3" /><pair ddi="false" e1="DDI-PubMed.19026171.s16.e2" e2="DDI-PubMed.19026171.s16.e2" /><pair ddi="false" e1="DDI-PubMed.19026171.s16.e2" e2="DDI-PubMed.19026171.s16.e3" /></sentence><sentence text=" The in vitro system can be used as a high-throughput model to screen similar compounds for the early identification of drug-drug interaction potential" /><sentence text="" /></document>